- NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD)
- NTLA-3001 is Intellia’s first wholly owned CRISPR-based in vivo targeted gene insertion candidate to advance into the clinic
- On track to dose the first patient in 2H 2024
CAMBRIDGE, MA, USA I July 30, 2024 I Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. AATD is a rare, genetic disease that most commonly manifests in lung dysfunction due to insufficient levels of alpha-1 antitrypsin (AAT) protein. NTLA-3001 is a systemically administered in vivo CRISPR/Cas9-based targeted gene insertion candidate. It is designed to precisely insert a healthy copy of the SERPINA1 gene, which encodes the AAT protein, with the potential to restore permanent expression of functional AAT protein to therapeutic levels after a single dose. This approach seeks to improve patient outcomes, including eliminating the need for weekly intravenous infusions of AAT augmentation therapy or lung transplant in severe cases.
“NTLA-3001 is a groundbreaking in vivo CRISPR-based gene insertion candidate designed to durably produce functional AAT protein at normal levels after a one-time treatment. We are excited to receive regulatory authorization to begin this important first-in-human study of NTLA-3001 for people living with AATD,” said Intellia President and Chief Executive Officer John Leonard, M.D. “In addition, this study serves to validate our modular gene insertion platform, which we plan to leverage to address numerous diseases caused by a missing or defective protein.”
The Phase 1/2 study will be an international, multicenter, single-arm, open-label study of NTLA-3001 in adults with AATD-associated lung disease. The study will enroll up to 30 patients and consist of a dose-escalation phase, followed by a dose-expansion phase to confirm the recommended dose. The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-3001. More information about the study may be found on clinicaltrials.gov when available.
Beyond its first application in the United Kingdom, Intellia is submitting additional regulatory applications in other countries as part of its ongoing, multi-national development strategy for NTLA-3001.
About NTLA-3001
NTLA-3001 is a wholly owned, first-in-class CRISPR-mediated in vivo targeted gene insertion development candidate for the treatment of AATD-associated lung disease. It is designed to precisely insert a copy of the SERPINA1 gene, which encodes the alpha-1 antitrypsin (AAT) protein, with the potential to restore permanent expression of functional AAT protein to therapeutic levels after a single dose. This approach seeks to improve patient outcomes, including eliminating the need for weekly intravenous infusions of AAT augmentation therapy or lung transplant in severe cases.
About Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that increases the risk of liver and lung disease. AATD is caused by changes in the SERPINA1 gene that normally provides instructions for making alpha-1 antitrypsin (AAT) protein in the liver that is then secreted to protect the lungs. Mutations to the SERPINA1 gene lead to the production of abnormal AAT protein that then accumulates in the liver. As a result, AAT protein levels in the blood and lungs are very low. The shortage of AAT in the blood and lungs places the lungs at risk for emphysema, a type of chronic obstructive pulmonary disease (COPD). AATD occurs in greater than 60,000 people in the U.S. and around 250,000 worldwide.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
SOURCE: Intellia Therapeutics
Post Views: 5,702
- NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD)
- NTLA-3001 is Intellia’s first wholly owned CRISPR-based in vivo targeted gene insertion candidate to advance into the clinic
- On track to dose the first patient in 2H 2024
CAMBRIDGE, MA, USA I July 30, 2024 I Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. AATD is a rare, genetic disease that most commonly manifests in lung dysfunction due to insufficient levels of alpha-1 antitrypsin (AAT) protein. NTLA-3001 is a systemically administered in vivo CRISPR/Cas9-based targeted gene insertion candidate. It is designed to precisely insert a healthy copy of the SERPINA1 gene, which encodes the AAT protein, with the potential to restore permanent expression of functional AAT protein to therapeutic levels after a single dose. This approach seeks to improve patient outcomes, including eliminating the need for weekly intravenous infusions of AAT augmentation therapy or lung transplant in severe cases.
“NTLA-3001 is a groundbreaking in vivo CRISPR-based gene insertion candidate designed to durably produce functional AAT protein at normal levels after a one-time treatment. We are excited to receive regulatory authorization to begin this important first-in-human study of NTLA-3001 for people living with AATD,” said Intellia President and Chief Executive Officer John Leonard, M.D. “In addition, this study serves to validate our modular gene insertion platform, which we plan to leverage to address numerous diseases caused by a missing or defective protein.”
The Phase 1/2 study will be an international, multicenter, single-arm, open-label study of NTLA-3001 in adults with AATD-associated lung disease. The study will enroll up to 30 patients and consist of a dose-escalation phase, followed by a dose-expansion phase to confirm the recommended dose. The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-3001. More information about the study may be found on clinicaltrials.gov when available.
Beyond its first application in the United Kingdom, Intellia is submitting additional regulatory applications in other countries as part of its ongoing, multi-national development strategy for NTLA-3001.
About NTLA-3001
NTLA-3001 is a wholly owned, first-in-class CRISPR-mediated in vivo targeted gene insertion development candidate for the treatment of AATD-associated lung disease. It is designed to precisely insert a copy of the SERPINA1 gene, which encodes the alpha-1 antitrypsin (AAT) protein, with the potential to restore permanent expression of functional AAT protein to therapeutic levels after a single dose. This approach seeks to improve patient outcomes, including eliminating the need for weekly intravenous infusions of AAT augmentation therapy or lung transplant in severe cases.
About Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that increases the risk of liver and lung disease. AATD is caused by changes in the SERPINA1 gene that normally provides instructions for making alpha-1 antitrypsin (AAT) protein in the liver that is then secreted to protect the lungs. Mutations to the SERPINA1 gene lead to the production of abnormal AAT protein that then accumulates in the liver. As a result, AAT protein levels in the blood and lungs are very low. The shortage of AAT in the blood and lungs places the lungs at risk for emphysema, a type of chronic obstructive pulmonary disease (COPD). AATD occurs in greater than 60,000 people in the U.S. and around 250,000 worldwide.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
SOURCE: Intellia Therapeutics
Post Views: 5,702
